636 related articles for article (PubMed ID: 11712796)
1. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
5. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
[TBL] [Abstract][Full Text] [Related]
6. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
8. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
10. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung carcinoma.
Koukourakis MI; Patlakas G; Froudarakis ME; Kyrgias G; Skarlatos J; Abatzoglou I; Bougioukas G; Bouros D
Anticancer Res; 2007; 27(5B):3625-31. PubMed ID: 17972527
[TBL] [Abstract][Full Text] [Related]
12. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
13. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
14. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
Manavis J; Ambatzoglou J; Sismanidou K; Koukourakis MI
Am J Clin Oncol; 2006 Oct; 29(5):479-83. PubMed ID: 17023783
[TBL] [Abstract][Full Text] [Related]
15. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Koukourakis MI; Kyrgias G; Papadopoulou A; Panteliadou M; Giatromanolaki A; Sivridis E; Mavropoulou S; Kalogeris K; Nassos P; Milioudis N; Touloupidis S
Anticancer Res; 2011 May; 31(5):1745-51. PubMed ID: 21617234
[TBL] [Abstract][Full Text] [Related]
16. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
Koukourakis MI; Tsoutsou PG; Abatzoglou I
Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
[TBL] [Abstract][Full Text] [Related]
17. Acute radiation dermatitis and pneumonitis in Japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy.
Osako T; Oguchi M; Kumada M; Nemoto K; Iwase T; Yamashita T
Jpn J Clin Oncol; 2008 May; 38(5):334-8. PubMed ID: 18417501
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
[TBL] [Abstract][Full Text] [Related]
19. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]